CY1122500T1 - Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων - Google Patents

Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων

Info

Publication number
CY1122500T1
CY1122500T1 CY20191101215T CY191101215T CY1122500T1 CY 1122500 T1 CY1122500 T1 CY 1122500T1 CY 20191101215 T CY20191101215 T CY 20191101215T CY 191101215 T CY191101215 T CY 191101215T CY 1122500 T1 CY1122500 T1 CY 1122500T1
Authority
CY
Cyprus
Prior art keywords
eosinophilic
treatment
pharmaceutical composition
composition containing
derivatives
Prior art date
Application number
CY20191101215T
Other languages
Greek (el)
English (en)
Inventor
Vladimir Evgenievich Nebolsin
Tatyana Alexandrovna Kromova
Anastasia Vladimirovna RYDLOVSKAYA
Alexander Grigorievich Chuchalin
Original Assignee
"ChemImmune Therapeutics" Limited Liability Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "ChemImmune Therapeutics" Limited Liability Company filed Critical "ChemImmune Therapeutics" Limited Liability Company
Publication of CY1122500T1 publication Critical patent/CY1122500T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • C07D211/88Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20191101215T 2013-11-14 2019-11-19 Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων CY1122500T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
PCT/RU2014/000855 WO2015072893A1 (ru) 2013-11-14 2014-11-12 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Publications (1)

Publication Number Publication Date
CY1122500T1 true CY1122500T1 (el) 2021-01-27

Family

ID=53057723

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101215T CY1122500T1 (el) 2013-11-14 2019-11-19 Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων

Country Status (23)

Country Link
US (2) US9949962B2 (enExample)
EP (2) EP3466425B1 (enExample)
JP (4) JP2016540749A (enExample)
KR (2) KR102312013B1 (enExample)
CN (2) CN110200968A (enExample)
AU (2) AU2014349246C1 (enExample)
BR (1) BR112016010515B1 (enExample)
CA (1) CA2930231C (enExample)
CY (1) CY1122500T1 (enExample)
DK (1) DK3069720T3 (enExample)
EA (4) EA032940B1 (enExample)
ES (2) ES2836887T3 (enExample)
HU (1) HUE046671T2 (enExample)
IL (2) IL245429B (enExample)
LT (1) LT3069720T (enExample)
MX (2) MX386887B (enExample)
PL (2) PL3069720T3 (enExample)
PT (1) PT3069720T (enExample)
RU (1) RU2552929C1 (enExample)
SG (1) SG10201900504XA (enExample)
SI (1) SI3069720T1 (enExample)
UA (1) UA118687C2 (enExample)
WO (1) WO2015072893A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MX380619B (es) * 2013-04-12 2025-03-12 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
US10370449B2 (en) 2014-02-28 2019-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
CN111093661B (zh) * 2017-09-07 2023-10-27 化学免疫疗法有限责任公司 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
CN113597328B (zh) 2019-03-21 2025-10-31 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
SG11202113310UA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4010001A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
WO2021207367A1 (en) * 2020-04-07 2021-10-14 Hofseth Biocare Asa Respiratory treatments using salmonid oil compositions
CN115803026A (zh) * 2020-06-26 2023-03-14 瓦伦塔有限责任公司 戊二酰亚胺衍生物用于治疗与异常白介素-6活性相关的疾病的用途
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196767A (ja) 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
AU9134191A (en) 1990-12-24 1992-07-22 Merrell Dow Pharmaceuticals Inc. Use of certain glutarimide derivatives in the treatment of depression and mania
AU6702894A (en) * 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
CA2466492A1 (en) 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
CN101848732B (zh) 2007-05-14 2013-06-05 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
MX380619B (es) 2013-04-12 2025-03-12 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.

Also Published As

Publication number Publication date
CA2930231C (en) 2022-06-14
MX2016006330A (es) 2016-09-06
IL271352A (en) 2020-01-30
JP2019214606A (ja) 2019-12-19
IL245429A0 (en) 2016-06-30
US10220029B2 (en) 2019-03-05
KR20200053639A (ko) 2020-05-18
EP3466425A1 (en) 2019-04-10
US20180104230A1 (en) 2018-04-19
EA201990529A1 (ru) 2019-07-31
BR112016010515B1 (pt) 2022-09-27
US20160279114A1 (en) 2016-09-29
EP3466425B1 (en) 2020-10-07
DK3069720T3 (da) 2019-11-25
IL245429B (en) 2020-02-27
AU2014349246B2 (en) 2018-10-18
EP3069720A1 (en) 2016-09-21
SG10201900504XA (en) 2019-02-27
PL3069720T3 (pl) 2020-05-18
EP3069720A8 (en) 2017-10-04
KR20160078400A (ko) 2016-07-04
CN105722511A (zh) 2016-06-29
LT3069720T (lt) 2020-01-10
EA201891262A1 (ru) 2018-10-31
JP2019055953A (ja) 2019-04-11
MX2019006881A (es) 2019-08-01
RU2552929C1 (ru) 2015-06-10
KR102312013B1 (ko) 2021-10-15
AU2018264084A1 (en) 2018-12-06
RU2013150861A (ru) 2015-05-20
EA032955B1 (ru) 2019-08-30
CN105722511B (zh) 2019-09-17
EA030961B1 (ru) 2018-10-31
JP6589251B2 (ja) 2019-10-16
JP6758677B2 (ja) 2020-09-23
EP3069720A4 (en) 2017-06-21
AU2018264084C1 (en) 2020-08-27
CA2930231A1 (en) 2015-05-21
JP2016540749A (ja) 2016-12-28
EA201690798A1 (ru) 2016-08-31
CN110200968A (zh) 2019-09-06
BR112016010515A2 (enExample) 2017-08-08
UA118687C2 (uk) 2019-02-25
AU2014349246A1 (en) 2016-05-19
PT3069720T (pt) 2019-12-02
EA037447B1 (ru) 2021-03-30
ES2836887T3 (es) 2021-06-28
EA032955B3 (ru) 2020-02-27
AU2018264084B2 (en) 2020-05-14
AU2014349246A9 (en) 2018-09-20
ES2759530T3 (es) 2020-05-11
KR102312294B1 (ko) 2021-10-15
SI3069720T1 (sl) 2020-02-28
WO2015072893A1 (ru) 2015-05-21
MX386887B (es) 2025-03-19
EA032940B1 (ru) 2019-08-30
EP3069720B1 (en) 2019-10-30
MX365781B (es) 2019-06-13
JP2020002152A (ja) 2020-01-09
PL3466425T3 (pl) 2021-04-06
AU2014349246C1 (en) 2019-02-21
US9949962B2 (en) 2018-04-24
EA201891261A1 (ru) 2018-10-31
HUE046671T2 (hu) 2020-03-30
IL271352B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CY1122500T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
MD4666B1 (ro) Inhibitori ai Syk
MX379264B (es) Profarmacos de amidas de piridona utiles como moduladores de canales de sodio.
MX2020004506A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
BR112015022551A2 (pt) inibidores de amido pirrol
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
BR112015022861A2 (pt) inibidores de bromodomínio
EA201691471A1 (ru) Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
IN2014DN09352A (enExample)
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
IN2014DN09348A (enExample)
MX2016002794A (es) Compuestos antiproliferativos.
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
MX380619B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
IN2014DN09347A (enExample)
PH12017500595B1 (en) Aldosterone synthase inhibitors